 Irvine, CA, June 02, 2021 GLOBE NEWSWIRE -- Odyssey Group International, Inc. OTCQB: ODYY the Company or Odyssey, a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of their novel nano-particle drug formulation. The drug formulation was designed to enhance brain distribution of its lead drug candidate, PRV-002, to treat concussion mild traumatic brain injury. 